Dolutegravir and Lamivudine for Pregnant Women with HIV
Treatments studied
Part of Infections clinical trials.
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HIV-1 infection with a viral load (amount of HIV in your blood) of at least 1,000 copies/mL
- You have never taken HIV medicines before, including PrEP or PEP in the last 6 months
- You are pregnant and no more than 32 weeks along, with a viable pregnancy
- You plan to continue your pregnancy
- You are at least 16 years old (or 15 in Brazil) and can provide informed consent
- You do not have active hepatitis B or C, severe liver or kidney problems, or active serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This study looks at whether two HIV medicines given as injections every 4 weeks—cabotegravir and rilpivirine—are safe and effective for pregnant women with HIV who have an undetectable viral load. The goal is to help pregnant people with HIV stay healthy and reduce the risk of passing HIV to their baby.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This study collects data from HIV patients who start treatment with a two-drug combination of dolutegravir and lamivudine, either as their first treatment or after switching from a three-drug regimen.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.